Hikma Pharmaceuticals Reappoints PwC as Auditor
Company Announcements

Hikma Pharmaceuticals Reappoints PwC as Auditor

Hikma Pharmaceuticals (GB:HIK) has released an update.

Hikma Pharmaceuticals has decided to reappoint PricewaterhouseCoopers LLP as its external auditor starting in 2026, following a competitive audit tender process. As part of regulatory requirements, Hikma must rotate auditors every 20 years, and this decision awaits shareholder approval at the 2026 Annual General Meeting. Investors may find this continuity in auditing services a point of stability for the company’s financial oversight.

For further insights into GB:HIK stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskHikma Pharmaceuticals Projects Strong Growth for 2024
TipRanks UK Auto-Generated NewsdeskHikma Pharmaceuticals Faces Shareholder Opposition on Buyback Waiver
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App